Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.

Article Details

Citation

Copy to clipboard

Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T

Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.

Leukemia. 2015 Sep;29(9):1939-42. doi: 10.1038/leu.2015.42. Epub 2015 Feb 13.

PubMed ID

25676420 [ View in PubMed

]

Abstract

Not Available

DrugBank Data that Cites this Article

Drugs

Radotinib